---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-059700"
form_type: "8-K"
ticker: "ZBIO"
cik: "0001953926"
company_name: "Zenas BioPharma, Inc."
filed_at: "2026-05-13T10:14:34+00:00"
generated_at: "2026-05-13T10:21:23.092217+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zenas BioPharma Q1 net loss $81M; obexelimab BLA on track

## Summary
- Net loss $81.0M in Q1 2026 vs $33.6M in Q1 2025; R&D expenses rose to $60.4M.
- Cash and investments $718.5M as of Mar 31; raised $419M year-to-date from offerings and debt facility.
- Obexelimab BLA for IgG4-RD expected this quarter; EMA filing H2 2026; INDIGO data at EULAR June 4.
- Phase 2 SunStone SLE trial enrollment completed; topline results expected Q4 2026.
- Director Tomas Kiselak did not stand for re-election; board size reduced by one.

## SEC filing metadata
- accession: 0001104659-26-059700
- form_type: 8-K
- ticker: ZBIO
- cik: 0001953926
- company_name: Zenas BioPharma, Inc.
- filed_at: 2026-05-13T10:14:34+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/tm2614295d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-059700
- JSON: https://secwatch.observer/filing/0001104659-26-059700.json
- Plain text: https://secwatch.observer/filing/0001104659-26-059700.txt

## Key facts
- Earnings Releases
  Zenas BioPharma, Inc. reported financial results for the quarter ended March 31, 2026.
  - Period: the quarter ended March 31, 2026
  - Result: reported results
  source text: On May 13, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm
- Executive change
  Tomas Kiselak resigned as director at Zenas BioPharma, Inc..
  - Action: resigned
  source text: Tomas Kiselak did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Kiselak’s term ended with his resignation from the Board of Directors of the Company, and the size of the Board of Directors was reduced by one.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm
- Shareholder Votes
  Zenas BioPharma, Inc. shareholders approved Election of two Class II directors to serve for three-year terms.
  - Proposal: director election
  - Outcome: passed
  source text: Proposal One : The stockholders elected each of the two nominees listed below as Class II directors to serve on the Company’s Board of Directors for a term of three years expiring at the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes James Boylan 44,083,930 4,121,508 2,499 4,458,184 Patrick Enright 44,253,715 3,951,474 2,748 4,458,184
  evidence_url: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm
- Shareholder Votes
  Zenas BioPharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-12-31
  source text: Proposal Two : The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 52,654,975 7,650 3,496
  evidence_url: https://www.sec.gov/Archives/edgar/data/1953926/000110465926059700/0001104659-26-059700-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.